Core Viewpoint - Syndax Pharmaceuticals reported a quarterly loss of $0.98 per share, which was better than the Zacks Consensus Estimate of a loss of $1.04, indicating an earnings surprise of 5.77% [1] Financial Performance - The company posted revenues of $20.04 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 36.69%, compared to zero revenues a year ago [2] - The current consensus EPS estimate for the upcoming quarter is -$0.99 on revenues of $17.81 million, and for the current fiscal year, it is -$3.99 on revenues of $81.74 million [7] Stock Performance - Syndax shares have increased by approximately 3.9% since the beginning of the year, while the S&P 500 has declined by 3.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Syndax belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Syndax Pharmaceuticals (SNDX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to the Syndax First Quarter twenty twenty five Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Sharon Clary, Head of Investor Relations at Syndax Pharmaceuticals. Speaker1 Great. Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's first quarter twenty twenty five financial and operating re ...

First Quarter 2025 Financial Results Presentation / May 5, 2025 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements of hi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...

Financial Performance - Syndax reported $20.0 million in net revenue from Revuforj in the first quarter of 2025, marking the first full quarter of its U.S. launch[5] - Niktimvo generated $13.6 million in net revenue in its first partial quarter of launch, with Syndax recording a $0.2 million share of the net commercial loss[10] - Product revenue for the first quarter of 2025 was $20,042,000, compared to $0 in the same period of 2024[34] - Net loss for Q1 2025 was $84,846,000, compared to a net loss of $72,400,000 in Q1 2024, indicating a 17.2% increase in losses[34] - Basic loss per share attributable to common stockholders was $0.98 in Q1 2025, compared to $0.85 in Q1 2024, reflecting a 15.3% increase[34] Expenses - Research and development expenses increased to $61.6 million in Q1 2025, up from $56.5 million in the same period last year, primarily due to axatilimab-related costs[12] - Selling, general and administrative expenses rose to $41.0 million in Q1 2025, compared to $23.0 million in the prior year, driven by increased employee-related expenses[13] - The company expects R&D expenses for Q2 2025 to be between $70 million and $75 million, with total expenses (R&D plus SG&A) projected at $110 million to $115 million[15] - Total operating expenses increased to $103,799,000 in Q1 2025, up from $79,514,000 in Q1 2024, representing a 30.5% increase[34] - Research and development expenses rose to $61,636,000 in Q1 2025, compared to $56,492,000 in Q1 2024, marking an increase of 9.5%[34] - Selling, general and administrative expenses increased significantly to $41,031,000 in Q1 2025 from $23,022,000 in Q1 2024, a rise of 78.3%[34] Cash and Assets - The company had cash, cash equivalents, and investments totaling $602.1 million as of March 31, 2025, expected to fund operations to profitability[9] - Cash, cash equivalents, and investments decreased to $602,135,000 as of March 31, 2025, down from $692,404,000 as of December 31, 2024, a decline of 13.0%[32] - Total assets decreased to $640,707,000 as of March 31, 2025, compared to $724,816,000 as of December 31, 2024, a reduction of 11.6%[32] - Total stockholders' equity fell to $215,059,000 as of March 31, 2025, down from $288,124,000 as of December 31, 2024, a decrease of 25.3%[32] - Common stock outstanding increased to 86,047,032 shares as of March 31, 2025, compared to 85,694,443 shares as of December 31, 2024[32] Product Development and Market Opportunities - Syndax plans to initiate multiple trials of revumenib in combination with standard care regimens for newly diagnosed acute leukemia patients starting in the second half of 2025[8] - The company submitted a supplemental New Drug Application (sNDA) for revumenib for the treatment of R/R mNPM1 AML in April 2025, seeking Priority Review[5] - Revuforj and Niktimvo are positioned to unlock multi-billion-dollar opportunities in their respective markets, supported by strong clinical data and ongoing trials[3]

– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – N ...

Conference ID: Syndax1Q25 Domestic Dial-in Number: 800-590-8290 International Dial-in Number: 240-690-8800 Live webcast: https://sndx-1q25.open-exchange.net/registration NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earn ...

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investor ...

Syndax Pharmaceuticals (SNDX) Q4 2024 Earnings Call March 03, 2025 06:57 PM ET Company Participants Sharon Klahre - Vice President of Investor Relations & CommunicationsMichael Metzger - CEO & DirectorSteve Closter - CCONeil Gallagher - President, Head of Research & DevelopmentKeith Goldan - Chief Financial OfficerBradley Canino - DirectorKelly Shi - Senior Vice PresidentYigal Nochomovitz - DirectorDavid Dai - DirectorGeorge Farmer - Managing DirectorAnjali Ganguli - Chief Strategy OfficerErik Lavington - E ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - CEO Steve Closter - CCO Neil Gallagher - President and Head of R&D Keith Goldan - CFO Anjali Ganguli - CSO Conference Call Participants Anupam Rama - JPMorgan Brad Canino - Stifel Peter Lawson - Barclays Chris Shibutani - Goldman Sachs Kelly Shi - Jefferies Michael Schmidt - Guggenheim Yigal Nochomovitz - Citi David Dai - UBS Justin Zelin - BT ...